---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029384"
form_type: "8-K"
ticker: null
cik: "0001697532"
company_name: "Applied Therapeutics, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:55:54.961383+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Applied Therapeutics raises $100M; FDA accepts govorestat NDA with Priority Review, PDUFA Aug 28

## Summary
- Private placement of 12,285,714 shares at $7.00/share and 2M pre-funded warrants at $6.999 for gross proceeds of ~$100M.
- FDA accepted NDA for govorestat (AT-007) for Classic Galactosemia with Priority Review; PDUFA target date Aug 28, 2024.
- Cash balance $43.6M as of Feb 23, 2024; combined with private placement proceeds and milestones expected to extend runway into 2026.
- Investors include Perceptive Advisors, Janus Henderson, Venrock, Adage Capital, Frazier Life Sciences, Logos Capital, others.
- Govorestat previously received Orphan Drug, Pediatric Rare Disease, and Fast Track designations; MAA under EMA review, decision expected Q4 2024.

## SEC filing metadata
- accession: 0001104659-24-029384
- form_type: 8-K
- cik: 0001697532
- company_name: Applied Therapeutics, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1697532/000110465924029384/0001104659-24-029384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1697532/000110465924029384/tm247481d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029384
- JSON: https://secwatch.observer/filing/0001104659-24-029384.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029384.txt

## Key facts
- Material Agreements
  Applied Therapeutics, Inc. entered into Securities Purchase Agreement with a select group of accredited investors valued at approximately $100 million (effective 2024-02-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a select group of accredited investors
  - Value: approximately $100 million
  - Effective: 2024-02-27
  source text: On February 27, 2024, Applied Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with a select group of accredited investors (collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1697532/000110465924029384/0001104659-24-029384-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.